Clinical trial · Interventional
Artificial Intelligence Models for Precision Prediction and Treatment of Prostate Cancer
Accurate Prediction and Treatment of Prostate Cancer by Artificial Intelligence Model-based Whole Slide Images and MRIs
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this clinical trial is whether artificial intelligence models can be used for accurate clinical preoperative diagnosis and postoperative diagnosis of pathological findings, and will also measure the accuracy of the predictions made by the artificial intelligence models.The main target questions addressed by the model building are: 1. whether the AI model can learn from preoperative MRI and postoperative Whole Slide Images so as to accurately predict information such as benignness or malignancy, aggressiveness, grading, subtypes, genes, etc. for participants suspected of having prostate cancer preoperatively/puncturally. 2. whether the AI model is capable of learning postoperative macropathology slides to enable outcome diagnosis of surgical pathology slides in new participants. Participants will: 1. complete an MRI examination and have their MRI images analysed by the established AI model to make an accurate diagnosis of them. 2. Based on the diagnosis, if prostate cancer is predicted, they will undergo radical prostate cancer surgery and refine their surgical pathology.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pathology | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
| Prostate Cancer Aggressiveness | — | UNRESOLVED | — |
| Prostate Cancer Stage | — | UNRESOLVED | — |
| Prostate Intraductal Carcinoma | Prostate Intraductal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Accurate Prediction Artificial Intelligence Models | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Experimental group
- description
- This group of patients will receive predictions assisted by artificial intelligence models.
- interventionNames
- Diagnostic Test: Accurate Prediction Artificial Intelligence Models
- type
- NO_INTERVENTION
- label
- Control Group
- description
- This group of patients will not receive predictions assisted by artificial intelligence models.
Primary outcomes (3)
- measure
- Prediction of postradical prostate cancer pathology after radical prostatectomy using the 'AUC' comprehensive assessment model
- timeFrame
- From subject enrolment to initial post-surgery, usually 30-90 days.
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 30 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with suspected PCa (elevated PSA or suspicious positive lesions on ultrasound or MRI results); Exclusion Criteria: * Previous treatment of the prostate in any form, including surgery, radiotherapy/chemotherapy, endocrine therapy, targeted therapy and immunotherapy; * Patients with any item missing from the baseline clinical and pathological information; * Patients with a history of other malignancies, serious comorbidities or other health problems; * Unable to provide/sign an informed consent form; * Patients who, in the judgement of the investigator, are deemed unfit to participate in this clinical trial;
References
Publications (0)
Data not yet available